Skip to main content
. 2015 Aug 14;10(4):1460–1466. doi: 10.3892/etm.2015.2681

Table I.

Baseline clinical characteristics of patients.

Characteristic Control group (n=15) Immunotherapy group (n=14) P-value
Gender (male/female) 14/1 14/0 0.368
Age (years, mean ± SD) 54.0±7.5 51.5±9.3 0.154
Maximum diameter of tumor (mm, mean ± SD) 25.14±7.87 23.79±7.30 0.845
Hepatitis B/C 14/1 14/0 0.368
Child-Pugh classification (A/B) 15/0 13/1 0.261
Pathology (Well/moderately/poorly-differentiated) 5/6/4 5/7/2 0.236
ALT (µ/l) 41.3±7.8 42.8±7.5 0.598
AST (µ/l) 46.1±7.2 46.4±7.9 0.252
Follow-up time (months) 16 19 0.663

SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase.